University of the Basque Country
Products and Services
Group capabilities:
The research activity of the NanoBioCel Group focuses on:
Microencapsulation of live cells: design and optimization of polymeric systems for immobilization of cells with therapeutic activity that protect against host immune response thanks to its technological design, resulting in a controlled release pharmaceutical system.
Micro and nanoparticles as delivery systems for peptide and protein vaccines: the results obtained so far by our group show that the use of these drug delivery systems can be quite useful in the development of vaccines since the encapsulation of antigens causes a significant and long-lasting immune response after administration by different routes to experimental animals (mice and monkeys).
Non-viral vectors for gene therapy: design and optimization of non-viral vectors based on lipid nanoparticles to carry therapeutic genes with the capacity to transfect eukaryotic cells.
Development of modified-release formulations: development and optimization of pharmaceutical forms based on new polymers for sustained drug release.
Biopharmaceutical and pharmacokinetic evaluation of modified release formulations and new therapeutic systems obtained with biotechnological products.
SEM scanning electron microscopy image of freeze-dried bioprinted scaffold based on hyaluronic acid.
Nanophomulations for pulmonary administration: the objective of this line of work is the design, optimization and characterization of vehicles for pulmonary administration. These systems have certain advantages such as mucoadhesion, being biodegradable and avoiding the first-pass effect. These systems are being applied for peptides, DNA, antineoplastics and antibiotics.
Development of scaffolds for tissue engineering and regenerative medicine, obtained by conventional techniques and by bioprinting techniques in 3D printers.
Development of bioinks for 3D bioprinting of scaffolds, organs and tissues.
Design and development of pharmaceutical dosage forms obtained by 3d Printing.
Interested in finding an investor or financial partner for:
- Development of nanoparticles for the treatment of ocular pathologies and neurodegenerative diseases and genetic diseases.
- Development of bio-inks for 3D bio-printing.
We can participate as partners in projects:
H2020 and Horizon Europe Program, Public-Private Collaboration, University-Company contracts related to:
- Drug formulation.
- Micro and nanoencapsulation of peptides, proteins, vaccines, DNA, RNA and biotechnological products.
- Bioink development projects for 3D bioprinting.
- Bioprinting of scaffolds for tissue engineering and regenerative medicine.
- Non-viral vectors for gene therapy.
Industrial partnership and commercialization:
We are in a position to advance the industrial development of:
- Lipid nanoparticles for ocular delivery.
- Formulation of vaccines, peptides and biotechnology products.
- Development of bioinks for 3D bioprinting.
- Developing 3D pharmaceutical dosage forms
- Non-viral vectors for gene therapy based in lipid nanoparticles
Characterization of the morphology of the 3D-printed scaffolds. (A) CAD designs (i–iii) and macroscopic images of the 3D-printed scaffolds (iv–vi). These scaffolds could also be printed in an automated way on culture plates (vii). (B) Cryo-SEM images of the surface of the scaffolds at different magnifications (from left to right: 120x, 300x, 1000x).
